French | English

Home : Investors > Publications > Quarterly financial information

Contact us

Questions about the Group, products, the financial statements?

> Please fill in this form

Where to meet us?

> View the Group's agenda

Quarterly financial information

13/05/2013

BioAlliance Pharma announces DSMB second positive recommendation to continue its Phase III clinical trial with Livatag® in primary liver cancer (PDF - 240 Ko)

15/04/2013

BioAlliance Pharma updates on major achievements of 2012 and publishes its 2012 consolidated financial statements and income for Q1 2013 (PDF - 166 Ko)

14/11/2012

Quarterly information as of September 30, 2012 - A dynamic progression of BioAlliance Pharma portfolio (PDF - 87 Ko)

17/04/2012

Full-year financial results for 2011 - Q1 2012 Consolidated turnover: A growth strategy focused on orphan oncology products, Promising products in advanced development, Reinforced cash reserves at €28.7 million as of December 31, 2011 (PDF - 185 Ko)

26/01/2012

2011 achievements and 2012 prospects - BioAlliance Pharma confirms the dynamics of its core business (PDF - 360 Ko)

14/11/2011

BioAlliance Pharma reports its consolidated turnover for Q3 and announces progress for Loramyc® commercialization in Italy (PDF - 305 Ko)

28/07/2011

Q2 2011: BioAlliance Pharma accelerates the progress of its “Orphan oncology products” portfolio and pursues its international partnerships on its “Specialty products” (PDF - 337 Ko)

13/05/2011

Q1 2011: achievement of key milestones in BioAlliance Pharma's clinical development program - Recurring revenue streams reflect the international deployment of Loramyc® (PDF - 80 Ko)

Next » 1 | 2 | 3 | 4